Research is being conducted on the use of SGLT2 inhibitors and GLP-1 receptor agonists in managing diabetes, cardiovascular disease, and renal outcomes. The potential benefits of combination therapy with these medications are being explored, particularly in relation to protecting against cardiovascular and renal complications in people with type 2 diabetes. The effectiveness of this approach in lowering the risk of chronic kidney disease and other related conditions is also being studied.